Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toho to Demand Fees to Makers for Services Using Meissa
November 30, 2009
- Chugai's Epogin Applied for Chemotherapy-Induced Anemia
November 30, 2009
- Xolair Recommended in JGL2009
November 30, 2009
- PI for Sancuso Completed in Japanese Volunteers: Solasia
November 23, 2009
- Merck's Merger with Schering-Plough Completed
November 23, 2009
- Avastin Approved for NSCLC in Japan: Chugai
November 23, 2009
- Yakult Aims at ¥10 Bil. Sales for Elplat with Stomach Cancer
November 23, 2009
- Sanofi-aventis, Micromet Sign License Agreement for BiTE Antibody
November 23, 2009
- Fludara Obtains Different Additional Indications for Tablet and Injectable
November 23, 2009
- Astellas to Overcome Prograf, Harnal Patent Expiration with New Products: President Nogimori
November 23, 2009
- Daiichi Sankyo Terminates Levofloxacin Patent Litigation
November 23, 2009
- Farletuzumab to Be Applied for in FY2012 in US: Eisai
November 23, 2009
- Santen: License Fees Boost Operating Profits Up 237%
November 23, 2009
- Freund Creates Subsidiary in Europe
November 23, 2009
- Subcutaneous Velcade in PIII in US: Takeda
November 23, 2009
- Kissei: Sales Driven by Urief
November 23, 2009
- NHI Price Listing for 394 Generic Products Announced
November 23, 2009
- Nexavar Enters PIII for Non-Responsive Thyroid Cancer: Bayer, Onyx
November 23, 2009
- Nippon Shinyaku: Sales Down 5.9%
November 23, 2009
- Strong Growth in Sales, Profits Reported by Top-4 Generic Makers
November 23, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…